Several reports have described consistent mutations in the REV3L gene in different cancer types, including, lung cancer, breast cancer, osteosarcoma, and head and neck cancer, and these mutations have been shown to confer tumorigenic properties [9, 11–13]. This evidence concerns the gene REV3L and breast cancer.